What is the role of diazoxide in the treatment of insulinoma?

Updated: May 31, 2020
  • Author: Zonera Ashraf Ali, MBBS; Chief Editor: Neetu Radhakrishnan, MD  more...
  • Print

Diazoxide is the drug of choice because it inhibits insulin release from the tumor. Adverse effects must be treated with hydrochlorothiazide. In patients not responsive to or intolerant of diazoxide (10%), a somatostatin analog may be indicated to prevent hypoglycemia.

Experience with systemic chemotherapy is limited. The traditional regimen of choice has been streptozocin and doxorubicin. Response rates as high as 69% have been reported but radiologic response is lower and due to uncertainty about efficacy and increased toxicity, this regimen is not accepted as a standard first-line therapy.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!